While Mereo Biopharma Group Plc ADR has underperformed by -0.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MREO rose by 51.52%, with highs and lows ranging from $5.02 to $2.23, whereas the simple moving average fell by -6.37% in the last 200 days.
On December 06, 2024, Jefferies started tracking Mereo Biopharma Group Plc ADR (NASDAQ: MREO) recommending Buy. A report published by Robert W. Baird on June 13, 2024, Initiated its previous ‘Outperform’ rating for MREO. BTIG Research also rated MREO shares as ‘Buy’, setting a target price of $4 on the company’s shares in an initiating report dated October 13, 2023. Cantor Fitzgerald Initiated an Overweight rating on August 12, 2022, and assigned a price target of $4. BTIG Research initiated its ‘Buy’ rating for MREO, as published in its report on May 05, 2021. Needham’s report from April 05, 2021 suggests a price prediction of $10 for MREO shares, giving the stock a ‘Buy’ rating.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Mereo Biopharma Group Plc ADR (MREO)
One of the most important indicators of Mereo Biopharma Group Plc ADR’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 6.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and MREO is recording 802.34K average volume. On a monthly basis, the volatility of the stock is set at 6.54%, whereas on a weekly basis, it is put at 6.87%, with a gain of 3.24% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.34, showing growth from the present price of $3.50, which can serve as yet another indication of whether MREO is worth investing in or should be passed over.
How Do You Analyze Mereo Biopharma Group Plc ADR Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.19%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 59.44% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
MREO shares are owned by institutional investors to the tune of 59.44% at present.
